Pretax income is the income that a company earns before paying income taxes. Evofem Biosciences's pretax income for the
three
months ended in Dec. 2023 was $-2.11 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Dec. 2023 was $53.00 Mil.
Evofem Biosciences's pretax margin was -43.69%.
During the past 12 years, Evofem Biosciences's highest Pretax Margin was 290.90%. The lowest was -31906.95%. And the median was -1472.03%.
Evofem Biosciences Pre-Tax Income Historical Data
The historical data trend for Evofem Biosciences's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Evofem Biosciences's Pre-Tax Income
For the Biotechnology subindustry, Evofem Biosciences's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evofem Biosciences's Pre-Tax Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Evofem Biosciences's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Evofem Biosciences's Pre-Tax Income falls into.
Evofem Biosciences Pre-Tax Income Calculation
This is the income that a company earns before paying income taxes.
Evofem Biosciences's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as
Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $53.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Evofem Biosciences (OTCPK:EVFM) Pre-Tax Income Explanation
Evofem Biosciences's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as
During the past 12 years, Evofem Biosciences's highest Pretax Margin was 290.90%. The lowest was -31906.95%. And the median was -1472.03%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Evofem Biosciences Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Evofem Biosciences's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Evofem Biosciences (Evofem Biosciences) Business Description
Evofem Biosciences Inc is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. The company's product, Phexxi (lactic acid, citric acid and potassium bitartrate), is a hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
EVFM has been successfully added to your 